A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R

Zhang, 2014, Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis, PLoS One, 9, e107161, 10.1371/journal.pone.0107161 Yang, 2015, Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials, Lancet Oncol, 16, 141, 10.1016/S1470-2045(14)71173-8 Lee, 2015, Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: a meta-analysis, J Clin Oncol, 33, 1958, 10.1200/JCO.2014.58.1736 Shigematsu, 2005, Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers, J Natl Cancer Inst, 97, 339, 10.1093/jnci/dji055 Riely, 2006, Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib, Clin Cancer Res, 12, 839, 10.1158/1078-0432.CCR-05-1846 Jackman, 2010, Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer, J Clin Oncol, 28, 357, 10.1200/JCO.2009.24.7049 Zhou, 2011, Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer, J Clin Oncol, 29, 3316, 10.1200/JCO.2010.33.3757 An, 2012, Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status, PLoS One, 7, e40109, 10.1371/journal.pone.0040109 Zhang, 2010, Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression, Mol Cancer, 9, 188, 10.1186/1476-4598-9-188 Chen, 2009, Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer, Pathol Oncol Res, 15, 651, 10.1007/s12253-009-9167-8 Hata, 2013, Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: comparison between T790M mutation-positive and mutation-negative populations, Cancer, 119, 4325, 10.1002/cncr.28364 Sun, 2013, Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors, Lung Cancer, 82, 294, 10.1016/j.lungcan.2013.08.023 Kuiper, 2014, Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients, Lung Cancer, 85, 19, 10.1016/j.lungcan.2014.03.016 Hata, 2015, Spatiotemporal T790M heterogeneity in individual patients with EGFR-mutant non-small-cell lung cancer after acquired resistance to EGFR-TKI, J Thorac Oncol, 10, 1553, 10.1097/JTO.0000000000000647 Matsuo, 2016, Association of EGFR exon 19 deletion and EGFR-TKI Treatment duration with frequency of T790M mutation in EGFR-mutant lung cancer patients, Sci Rep, 6, 36458, 10.1038/srep36458 Nosaki, 2016, Re-biopsy status among non-small cell lung cancer patients in Japan: a retrospective study, Lung Cancer, 101, 1, 10.1016/j.lungcan.2016.07.007 Yang, 2017, Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA Study phase II extension component, J Clin Oncol, 35, 1288, 10.1200/JCO.2016.70.3223 Goss, 2016, Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study, Lancet Oncol, 17, 1643, 10.1016/S1470-2045(16)30508-3 Mok, 2017, Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer, N Engl J Med, 376, 629, 10.1056/NEJMoa1612674 Oxnard, 2011, Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation, Clin Cancer Res, 17, 1616, 10.1158/1078-0432.CCR-10-2692 Chmielecki, 2011, Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling, Sci Transl Med, 3, 90ra59, 10.1126/scitranslmed.3002356 Eck, 2010, Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer, Biochim Biophys Acta, 1804, 559, 10.1016/j.bbapap.2009.12.010 Furuyama, 2013, Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors, Cancer Sci, 104, 584, 10.1111/cas.12125 Zhu, 2008, Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals, Cancer Lett, 265, 307, 10.1016/j.canlet.2008.02.064 Mok, 2009, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma, N Engl J Med, 361, 947, 10.1056/NEJMoa0810699 Sequist, 2008, First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations, J Clin Oncol, 26, 2442, 10.1200/JCO.2007.14.8494 Wu, 2014, Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial, Lancet Oncol, 15, 213, 10.1016/S1470-2045(13)70604-1 Sequist, 2011, Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors, Sci Transl Med, 3, 75ra26, 10.1126/scitranslmed.3002003